Linzagolix reduces HMB in women with uterine fibroids
27 Jul 2020
bởiElaine Soliven
The use of linzagolix, a new oral gonadotropin-releasing hormone (GnRH) antagonist, with or without add-back therapy (ABT) significantly reduces heavy menstrual bleeding (HMB) in women with uterine fibroids, according to the PRIMROSE 2* trial presented at ESHRE 2020.